Background New pharmacovigilance legislation allows consumers to report adverse drug reactions (ADRs) directly to competent authorities in all European Union countries. Consumer reporting is available in Portugal since July 2012. In 2013, the National Pharmacovigilance System (SNF) had received 3461 spontaneous ADR reports, of which only 1.4 % (n = 50) were from consumers. Consumer reporting could be one opportunity to reduce underreporting. Aim The aim of this study was to describe the attitudes and knowledge of the general public regarding spontaneous reporting and the reasons and opinions that can influence consumers' ADR underreporting. Methods A descriptive-correlational study was performed looking for consumers' attitudes and knowledge regarding spontaneous reporting. A 6-month survey was conducted from June to November 2013 in general adult consumers from a community pharmacy in Coimbra, Portugal, who used prescribed medicines or over-the-counter (OTC) drugs. Attitudes and opinions were surveyed by personal interview in a closedanswer questionnaire using a Likert scale. Questionnaires from healthcare professionals or incomplete ones were not considered. Data were analyzed using descriptive statistics, chi-square (χ 2 ) tests, and Spearman's correlation coefficients. Results One thousand eighty-four questionnaires were collected (response rate of 81.1 %) and 948 completed were selected for analysis. Of the respondents, 44.1 % never heard about SNF. Younger people and those with a higher education were significantly more likely to be aware of SNF. Only one consumer had previously reported directly an ADR. Reporting ADRs indirectly through a healthcare professional (HCP) was preferred by 62.4 %. The main reasons for consumers reporting spontaneous ADR would be the severity of reactions (81.1 % agreed or strongly agreed) and worries about their situation (73.4 % agreed or strongly agreed). Only weak and moderate correlations were found between studied statements.. Conclusions Consumers are more likely to do spontaneous report about severe reactions or if they are worried about the symptoms. Tailored and proactive information on ADR reporting and educational interventions on consumers could increase the number of reports from consumers in Portugal.
Introduction
Voluntary adverse drug reaction (ADR) reporting is one of the most versatile pharmacovigilance methods, because, among other advantages, it covers the entire population as well as all drugs throughout their commercial life [1] , being also a method that provides the highest volume of information with relatively lower maintenance cost than other pharmacovigilance methods [2] .
The new European legislation about pharmacovigilance that came into force last July 2012 [3] is the biggest change in the human medicine regulation in the European Union (EU) since 1995. The importance of direct consumer reporting has been highlighted by this new European legislation that guides member states to take all appropriate measures to encourage patients to report suspected ADRs to the national authorities of European Union countries [3] .
Patients' contribution still represents a relatively small percentage of total reports in most countries within the EU [4] [5, 6] . The number of countries who encourage consumers to report ADRs has increased, and a guideline has been developed for setting up patient reporting systems. Most of EU countries have very recently started with reporting systems for the general public, mostly created by imposition of international guidelines [3] , so the amount of reports received from consumers is very low and has weak significance in earlier detection of ADRs in many countries. However, the increase in quantity of the number of reports received should ideally in time be reflected in an increased quality and faster signal detection. So far, the quality of patient reports appears to be similar to that of healthcare professional (HCP) reports [7] . Studies have also shown the possible benefits of patient reporting for signal detection [8, 9] .
The Portuguese National Pharmacovigilance System (SNF) was created centrally in 1992, and it is a key tool for monitoring and ensuring the safety of patients, with a view to the protection of public health. Since 1999, regional centers have been created to collect suspected reports of ADRs from healthcare professionals and to encourage reporting, involving universities to promote their scientific and technical expertise and spread the system [10] . Actually, the SNF is coordinated by the INFA RMED, IP-(National Authority of Medicines and Health Products), and composed of four regional pharmacovigilance units that covers the entire region of Portugal.
Consumer reporting is available in Portugal since July 2012 and in 2013, the SNF had received 3461 spontaneous ADR reports, of which only 1.4 % (n = 50) were reported by consumers.
The objective of this survey was to describe the attitudes and knowledge of the consumers regarding spontaneous reporting and the factors that can influence consumers' ADR underreporting in Portugal, to gain insight into why consumers do not report more and how to possibly tackle this problem in Portugal.
Methods
A descriptive-correlational study was conducted looking for consumer' attitudes and knowledge regarding spontaneous reporting. Consumers were asked about the reasons to report and opinions about reporting ADRs. The current study provides an adequate exploration about what motivates consumers to report an ADR and the reasons and opinions about reporting.
Questionnaire design
Based on information on consumer/patient reporting in the literature, a survey was created in order to describe the attitudes and knowledge of the consumers regarding spontaneous reporting and the factors that can influence consumers' ADR underreporting in Portugal.
The questionnaire was based and adapted from previous studies [11] [12] [13] [14] and translated to Portuguese by the author. The Portuguese questionnaire was field tested by several volunteer consumers (n = 28), not included in the sample, in order to improve the translation and the understanding of the questionnaire. The final questionnaire includes two major sections: Section I asks about respondents' characteristics (gender, age, education, and working status) and Section II relates to reporting attitudes and knowledge of the respondents about reporting.
The reasons and opinions were rated with a five-point Likert scale (strongly agree to strongly disagree), where the middle position was labeled Bneutral^to reflect a neutral position, and not an inability to answer the question. The main results are presented in Tables 2 and 3 .
The data collection
Data were collected during 6 months (from June to November 2013) by the author. A large group of medicines' consumers of a community pharmacy were selected as possible respondents, and questionnaires were administered by personal interview. A convenience sample was used in order to collect data from medicines' consumers.
Study population
The target population included the medicine consumers of a community pharmacy in Coimbra, Portugal, who were invited to participate in the survey, with a personal interview. A total of 80,743 dispensations were performed during the 6-month study period. The main inclusion criteria included people who were dispensed prescribed medicines or bought over-thecounter (OTC) medicines and who accepted to participate in the study. Another inclusion criterion was age: consumers under 18 years were not included. A record was made to avoid duplicate inclusions. The individual questionnaire was anonymous, and the data were intended only for scientific purposes of this study and were stored in agreement with privacy regulations. Participants signed an informed consent to take part in the study.
Data analysis
Descriptive statistics provided an overview of the respondent characteristics (Table 1) , the reasons for reporting ADRs (Table 2) , and the opinions of consumers on reporting ADRs (Table 3) . A Pearson chi-square (χ 2 ) test was performed to detect significant differences in answers between gender, age, and educational level. Significance was based on a two-sided χ 2 test and significance was set at p < 0.05. If the expected counts in the contingency table are less than 5, the results from the chi-square test are not statistically valid and Fisher's exact test could be used. Since age categories and educational level can be seen as ordered categorical variables, we also calculated the χ 2 test for trend (depicted as the linearby-linear association in the Statistical Package for the Social Sciences (SPSS) output). Significance was set at T value p < 0.05. Correlations were calculated to measure possible relationships between two or more statements. Because the data were measured at the ordinal level (Likert scale), Spearman's correlation coefficient (r) was used in this analysis. In this study, a correlation was considered strong if r > 0.7, moderate if r > 0.4 and <0.7, and weak if r < 0.4 [15] . The anonymized data were entered and subsequently analyzed using IBM®-SPSS software version 20.0 for Windows.
Results
A total number of 1337 individuals were approached for a face-to-face interview. There were 1084 respondents, leading to a response rate of 81.1 %. Of the responses, two questionnaires were not completed and were not taken into account. Among the 1082 questionnaires with totally completed responses, there were 134 responses Data on motives are given as the percentage of total responses with the frequency (n) of the responses given in parenthesis. Most frequently reported responses are given in italics. Adapted from van Hunsel et al. [17] (12.4 %) by HCPs that were also excluded for data analysis due to the bias created by these answers. The characteristics of the respondents are given in Table 1 and the agreements to the statements are given in Tables 2 and 3 , showing the distribution of responses on the statements about reasons for reporting ADRs and the opinions about reporting ADR, respectively.
Consumers' attitudes and knowledge
Regarding attitudes and knowledge, 44.1 % of consumer s never heard about SNF and 13.3 % never heard about the possibility of reporting/sharing experiences of an ADR with an HCP or directly to the SNF. A total of 53.4 % knew about the SNF and the possibility to report an ADR. Since age categories and educational level can be seen as ordered categorical variables, we also calculated the χ 2 test for trend (depicted as the linear-by-linear association in the SPSS output). Significance was set at T value p < 0.05 in the results we depict.
Younger people were significantly more likely to be aware of SNF (χ 2 , p = 0.002, T value 0.004). There is also a difference in people from different age categories that know about the possibility of reporting (χ 2 , p = 0.015); however, there was no trend when looking at the categories (T value 0.099). The classes 35-44 years and 45-54 years know more about the possibility of reporting.
Based on educational level, people with a higher level of education were significantly more likely to be aware of SNF (χ 2 , p ≤ 0.001, T value <0.001) and to know about the possibility of reporting/sharing an ADR (χ 2 , p ≤ 0.001, T value <0.001).
Of the respondents, 57.6 % had the perception that they had already suffered an ADR, although only one consumer had previously reported an ADR directly to SNF. Another two had reported through an HCP.
All consumers who already experienced an ADR but who did not report it (n = 543), were questioned about reasons for non-reporting, stated that Bside effects were not serious enough^(n = 145) and Bthe side effect was expected/known( n = 106). On the other hand, consumer who never suffered from an ADR (n = 402) received a question about the attitudes for the future: only 49.8 % of the respondents who never had side effects from any medicine stated that in the future, they would report if they had any side effect.
When asked for what they do when they have an ADR, consumers answered that they talk to their GP (35.9 %) or to their pharmacy (33.7 %). Making a spontaneous report was also pointed out by 32.2 % of respondents as an action to do when they have an ADR, but only three of the respondents had already made a spontaneous report. Stopping the medication was mentioned by 17.1 % of respondents (n = 162) and few consumers, 5.3 %, said that they did not do anything (n = 50).
With concern to motives for reporting and opinions about reporting, the main reasons (Table 2) for consumers to do a spontaneous report would be the severity of the reaction and worries about their own situation. Regarding opinions (Table 3) , consumers believe that reporting an ADR can prevent harm to other people and that reporting contributes to research and knowledge or drug improvement. Consumers also consider that it was difficult to discuss the ADR with HCPs, such as general practitioners or pharmacists.
Consumers' characteristics, knowledge regarding SNF, and the opportunity to report ADR were compared with the other [17] answers. Based on Pearson's chi-square statistics, significant results are given, indicating that the answers were related to consumer characteristics. After subdividing the answers on the statements based on the respondent characteristics, it appeared that gender, age, and level of education had a significant effect on the reasons to report an ADR and/or the opinions about reporting ADRs and also for the knowledge about the possibility of reporting an ADR and/or about the existence of SNF. In general, older consumers and those with lower educational level had demonstrated lower levels of knowledge in relation to pharmacovigilance and ADR reporting. The highest Spearman's correlation coefficient found in the present data was 0.54 for the relation between opinion 3 and opinion 4-BReport ADR present in the leaflet is useless^and Bonly report ADR if it is serious.^This means that a strong correlation between statements was not present, and only moderate and weak correlations were found. Therefore, it was difficult to define the meaning of the possible relationships between the statements.
Discussion
The questionnaire resulted in a high response rate of 81.1 %, but about 12 % of respondents were HCPs who were excluded from data analysis due to the possible bias created by their knowledge regarding study issues. The high number of HCPs interviewed is for sure related to the existence of a huge healthcare pole in Coimbra, which is one of the biggest employers of the central region of Portugal. Regarding this, the high percentage of respondents who knows about the SNF and the possibility to report an ADR could be related to the proximity to healthcare pole and the existence of patients-HCP proximity that increases the level of knowledge regarding health issues, due to social relation bias: 55.9 % of respondents knows about SNF and 86.7 % knows that it is possible to report an ADR, either to SNF directly or through an HCP; these possibilities were learned mainly from practitioners and/or pharmacy. As far as the authors know, no major activities were conducted by SNF for consumers regarding information on spontaneous reporting. Comparing the knowledge about the ADR reporting, our results are consistent with earlier studies [11, 13] regarding how respondents learned about the possibility of reporting possible ADRs, which shows that most of consumers learned it from their pharmacy or GP.
Despite of knowing about the SNF, for 62.4 % of the respondents, the best way to report is indirectly through an HCP, which we could relate to indifference, ignorance of reporting directly, and insecurity to determine causal relationship between the drug and the reaction, already described by Inman as reasons for underreporting [16] . Despite all efforts to potentiate the online reporting, only 31.6 % of respondents prefer this method above other methods. This result is consistent with the SNF results, and online reporting is still little used in Portugal [17] .
Performing a spontaneous report was also pointed by 32.2 % of respondents as an action to do when they have an ADR, but only 3 of the respondents had already made a spontaneous report. However, Coimbra, where this study was performed, is located in central Portugal which is the geographic region that receives less ADR reports [17, 18] . The mode of questionnaire administration is likely to affect the quality and quantity of data collected. Social interaction between the interviewer and respondent can lead to respondents taking social norms into account when responding, resulting in social desirability bias. The bias could be even stronger due to the personal interview used and could be a reason for the contradictory results presented.
Several studies have been conducted with the aim of investigating motivations of healthcare professionals for reporting ADRs [1, 19] [20] [21] [22] [23] [24] [25] [26] [27] . The severity of the reaction was the main factor determining the ADR report or not [27] . Hasford et al. [21] and Ekman et al. [20] indicated that the severity of the reaction, unusual reactions, and reactions caused by a new drug were the main reasons motivating HCP to report ADRs. The desire to contribute to medical knowledge, reaction previously unknown to the reporter, reaction to new drug, desire to report all significant reactions, known association between drug and reaction, and severity of reaction are also motives that encourage HCP to report an ADR [28] .
As shown by Inman, there are several reasons related to knowledge and attitudes that could be related to underreporting. The reasons found by HCP could easily be demonstrated as the same by consumers. Complacency ("side effect not serious enough"), diffidence (Bit's unnecessary^), ignorance and indifference ("expected/knew side effect"), and insecurity ("didn't realize that side effect is due to the medicine") are pointed as the main reasons for not reporting the experienced side effects [16] .
Some of the motives found for HCPs are also important reasons for consumers to report, such as severity of the reaction and wanting to contribute to medical knowledge. According to a similar study conducted in The Netherlands in patients that already sent a spontaneous report to Netherlands , Pharmacovigilance Centre-Lareb [14] , "the severity of the adverse reaction" and the Bneed to sharing experiences^were the main reasons of patient reporting.
It appeared that consumers are motivated to report ADR due to several reasons. The most important motives are the severity of the reaction (81.1 % agree or strongly agree), and they were worried about their situation (73.4 % agree or strongly agree). The need to be heard (63.6 % agree or strongly agree) and difficulty to discuss the ADR with a medical practitioner or pharmacist (62.9 % agree or strongly agree) were also main factors to do spontaneous report directly by consumer s. The need to be heard and the difficulty to discuss the ADR with HCP suggest that communication between patient and HCP should be improved. It can also reflect the insecurity regarding identification of ADR and the acknowledgement of HCP [16] . Furthermore, communication with HCP is a major barrier indicated by patients to do a spontaneous report. The HCP-patient communication barrier has also been discussed in other studies: the issue of dismissive attitudes among HCPs and their failure to report ADRs has been discussed [11, 29] , and some consumers were concerned that GP reports may not always be accurate and that doctors may not even consider suspected ADRs, indicating that the severity of symptoms may be perceived differently by patients [30] and that patient reports might differ from those of HCP [31] .
Among the altruistic motives described in the literature, preventing harm to other patients, making the ADR publicly known, increasing medical knowledge, and wanting to improve the patient information leaflet were indicated as reasons to report [14] . Personal motives to report an ADR included wanting more information about the ADR, indicating that the ADR was too severe not to report, being angry, or wanting confirmation of their ADR [14] . Other studies also expressed altruistic views indicating the need to make the ADR public or making other patients aware of side effects from medicines and also to prevent others from suffering similar problems [11] . The importance of highlighting the patients' perspective on suspected ADRs, particularly their severity and impact, was also described by Anderson et al. [11] ; unexpected reactions to a widely used medicine and worse side effects than the underlying medical problem were also motives among reporters in UK [11] .
Furthermore, in this study, patients believe that reporting an ADR can prevent harm to other people (88.2 % agree or strongly agree), that reporting contributes for improvement of the drugs (82.9 % agree or strongly agree) and to research and knowledge (79.8 % agree or strongly agree) (Tables 2 and  3 ). However, respondents did not show so much altruistic motives which concerns to consumer attitudes and knowledge on reporting.
Comparing the attitudes concerning the type of reactions to be reported, there are also some interesting findings. Consumers states that Breporting an ADR present in the patient information leaflet is useless^(60.2 %) and BI only report if the ADR is serious^(66.9 %): this ignorance about the types of reactions that should be reported should be addressed by providing useful information to patients; on the other side, Bthe ADR was not mentioned in the leaflet^(33.6 %) and Breporting an ADR if it is unexpected^(50.1 %) were not pointed as major reasons to report, which could represent insecurity from patients to establish causal relation, or even complacency that medicines are safe and ADR are well documented by the time the drug is marketed.
Several statements used in the questionnaire to assess the reasons and opinions of consumers may be related and have similar meaning. Nevertheless, the Spearman's correlation coefficients between statements were calculated and strong correlations are not present. Furthermore, moderate and weak correlation coefficients between the statements were found. Mostly significant related reasons could be easily explained: The difficult to discuss an ADR (reason 3) with HCP and the wanting to be heard (reason 5) could be explained with the communication barrier already discussed. Furthermore, these statements are also related with the angry about their situation (reason 7) and the wanting for action to be taken (reason 8). The opinions that ADR reporting could contribute to research, knowledge, and development of drugs (opinion 5 and 8) are also related aspects with the possibility to prevent harm to other people (opinion 1).
Portuguese consumers also pointed out being angry about their situation as a main motive to report an ADR. It could reflect that ADR knowledge should be improved among consumers and the ADR should be clarified to the patients, in order that they understand that is an inherent possibility of the medicines use.
A final statement intended to understand the action of consumers if they experience a possible ADR in the future shows an evident difference with the previously performed study in The Netherlands. Only 38.8 % of Portuguese consumers appear to be motivated to do a report of ADR in future. About one third are not sure about what to do and 28.1 % even say that they would not report. This could be explained by the fact that our respondents never reported an ADR before, contrary to the patients of a Dutch study.
Consumers have potential to contribute with useful information on drug safety, which should be maximized. Because HCPs and consumers have different views regarding ADR reporting, in daily practice, it is important to receive reports from both groups to assess the true nature of the ADR. Consumer reporting has already shown important and valuable information on drug safety. Despite of this, this contribution can be maximized.
Strengths and weaknesses of the study
Of the 1337 questionnaires delivered, 1082 has completed the questionnaire. Of this, 87.6 % (n = 948) were taken into account for data analysis. In order to study the representativeness of the sample, variables under study was compared with the general Portuguese population characteristics. In this study, there is an underrepresentation of the elderly class of 65+ years compared to the Portuguese population. With concern to education, the discrepancies are even more evident. There is an underrepresentation of classes with lower literacy, resulting in an overrepresentation of tertiary education classes. Although, we thought that the results reflect the trend of the general population concerning to attitudes and knowledge regarding ADR report; however, despite of the high response rate that could be considered one of the strengths of the study, caution is needed before extrapolating these data to the general population, because older [32] or lower-literacy populations cannot be represented correctly. Gender does not appear to have interfered with the results.
Besides the high response rate, the use of personal interviews could have a negative social desirability bias, leading to biased answers. Social interaction between the interviewer and respondent can lead to respondents taking social norms into account when responding, resulting in social desirability bias. Additionally, interviewer can also cause biases due to the reluctance caused in people to reveal beliefs unlikely to be endorsed by the interviewer.
Also, proper randomization was not possible in selecting respondents, mainly due to the selection method of sampling (convenience sample). Comparison of data collected with other studies carried on patients that already report ADR could reflect inconclusive and non-comparable results.
Despite of our study being conducted similarly to previous studies, the differences in responses between reporters and non-reporters are evident. It can be easily understood that these differences in results are based on the fact that our respondents never made a spontaneous reporting before and are due to lower knowledge shown regarding pharmacovigilance.
This study gained insight into the attitudes and behavior of patients who never reported an ADR with respect to the future behaviors. Few studies are available about the reasons or motives why patients actually report suspected ADRs. As far as we know, this is the first study performed in Portugal regarding patients' attitudes and knowledge about ADR reporting. Further opportunity for a purposive sample of reporters to describe their opinions should be taken, comparing attitudes, knowledge, and experiences of different countries in order to better understand what strategies to adopt to increase the sensibility of patients for spontaneous reporting. However, consumers who had reported to the SNF constitute a minority of the population. This study allows us to understand which attitudes are changeable in patients who had not reported before in order to motivate consumers to be active in ADR reporting and pharmacovigilance.
Conclusion
Based on the results of our survey, a large part of the respondents know about the SNF and the possibility of reporting an ADR, directly to SNF or through an HCP. However, underreporting among consumers is very evident and there is a great need to create awareness and to promote the reporting of ADRs for general public reporting.
The main motives to report an ADR were the severity of the reaction and worries about their own situation. Consumers believe that reporting an ADR can prevent harm to other people and that reporting contributes to research and knowledge or drug improvement, reflecting altruistic opinions about reporting. Although, respondents also consider that it was difficult to discuss the ADR with HCPs, showing that there is a communicative barrier that must be exceeded. Only three consumers have already reported an ADR, one directly and two through HCP, so more information and intervention is needed in patients, in order to improve reporting rates.
